Chemotherapy for advanced pancreatic cancer: Past, present, and future

Current Oncology Reports

Volumn 7, Issue 3, 2005, Pages 186-195

  Friberg, Gregory ^a   Kindler, Hedy Lee ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CI 779; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXATECAN; FLUOROURACIL; GEMCITABINE; GIMESTAT; IMATINIB; IRINOTECAN; ISIS 2503; IXABEPILONE; K RAS PROTEIN; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LONAFARNIB; LY 29311; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; ONCOPROTEIN; OTASTAT; OXALIPLATIN; PEMETREXED; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RALTITREXED; RUBITECAN; SORAFENIB; TANOMASTAT; TEGAFUR; THALIDOMIDE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MORBIDITY; NEPHROTOXICITY; NEUTROPENIA; ONCOGENE H RAS; ONCOGENE K RAS; PANCREAS CANCER; QUALITY OF LIFE; STOMACH DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 18744407041     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0072-3     Document Type: Article

References (59)

1. Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Carter SK, Comis RL: The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975, 2:193-214.
3. Van Rijswijk RE, Jeziorski K, Wagener DJ, et al.: Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 2004, 40:2077-2081.
4. Rubin J, Gallagher JG, Schroeder G, et al.: Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma. Cancer 1996, 78:1888-1891.
5. Fung MC, Takayama S, Ishiguro H, et al.: [Chemotherapy for advanced or metastatic pancreatic cancer: analysis of 43 randomized trials in 3 decades (1974-2002)]. Gan To Kagaku Ryoho 2003, 30:1101-1111.
6. Casper ES, Green MR, Kelsen DP, et al.: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994, 12:29-34.
7. Rothenberg ML, Moore MJ, Cripps MC, et al.: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996, 7:347-353.
8. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
9. Storniolo AM, Enas NH, Brown CA, et al.: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999, 85:1261-1268.
10. Tempero M, Plunkett W, Ruiz Van Haperen V, et al.: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21:3402-3408.
11. Oliani C, Padovani M, Manno P, et al.: Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. Anticancer Res 2004, 24:2107-2112.
12. Correale P, Messinese S, Marsili S, et al.: A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid. Br J Cancer 2003, 89:239-242.
13. Berlin JD, Catalano P, Thomas JP, et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002, 20:3270-3275.
14. Kindler HL, William D, Hochster H, et al.: Clinical outcome in patients (pts) with advanced pancreatic cancer treated with pemetrexed/gemcitabine [abstract]. Proc ASCO 2002, 21:499.
15. Richards DA, Kindler HL, Oettle H, et al.: A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer [abstract]. Proc ASCO 2004, 23:4007.
16. Cartwright TH, Cohn A, Varkey JA, et al.: Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20:160-164.
17. Hess V, Salzberg M, Borner M, et al.: Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003, 21:66-68.
18. Scheithauer W, Schull B, Ulrich-Pur H, et al.: Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003, 14:97-104.
19. Okada S, Okusaka T, Ueno H, et al.: A phase II and pharmacokinetic trial of S-1 in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2002, 21:682.
20. Nakamura K, Yamaguchi T, Ishihara T, et al.: A phase I/II study of gemcitabine (GEM) with oral S-1 in metastatic pancreatic carcinoma [abstract]. Proc ASCO 2004, 23:4134.
21. Philip PA, Zalupski MM, Vaitkevicius VK, et al.: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001, 92:569-577.
22. Heinemann V, Quietzsch D, Gieseler F, et al.: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma [abstract]. Proc ASCO 2003, 22:1003.
23. Reni M, Passoni P, Panucci MG, et al.: Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001, 19:2679-2686.
24. Reni M, Cordio S, Passardi A, et al.: Final results of a phase III trial of gemcitabine (G) versus PEFG regimen in stage IVA or metastatic pancreatic adenocarcinoma (PA) [abstract]. Proc ASCO 2004, 23:4010.
25. Louvet C, Labianca R, Hammel P, et al.: GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non-resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III [abstract]. Proc ASCO 2004, 23:4008.
26. Rocha Lima CM, Green MR, Rotche R, et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004, 22:3776-3783.
27. Burtness B, Sipples R, Mirto G, et al.: Phase II trial of irinotecan/docetaxel combination for advanced pancreatic cancer [abstract]. Proc ASCO 2004, 23:4116.
28. Cheverton P, Friess H, Andras C, et at.: Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2004, 23:4005.
29. O Reilly EM, Abou-Alfa GK, Letourneau R, et al.: A randomized phase III trial of DX-8951f (exatecan mesylate, DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) [abstract]. Proc ASCO 2004, 23:4006.
30. Schneider BP, Ganjoo KN, Seitz DE, et al.: Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003, 65:218-223.
31. Kulke M, Niedzwiecki D, Tempero M, et al.: A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/irinotecan in patients with metastatic pancreatic cancer (CALGB 89904) [abstract]. Proc ASCO 2004, 23:4011.
32. Whitehead R, McCoy S, Rivkin S, et al.: A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: a Southwest Oncology Group Study [abstract]. Proc ASCO 2004, 23:4012.
33. Milella M, Gelibter A, Di Cosimo S, et al.: Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004, 101:133-138.
34. Van Laethem J, Polus M, Marechal R, et al.: Gemcitabine and oxaliplatine (GEMOX) in gemcitabine-refractory advanced pancreatic cancer: a phase II study. Proc ASCO 2004, 23:4119.
35. Pelzer U, Hempel C, Stieler J, et al.: Oxaliplatin (OXA) in combination with high dose 5-FU (24h)/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer [abstract]. Proc ASCO 2002, 21:684.
36. Ulrich-Pur H, Raderer M, Verena Kornek G, et al.: Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003, 88:1180-1184.
37. Jacobs A, Burris HA 3rd, Rivkin S, et al.: A randomized phase III study of rubitecan (ORA) vs best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study [abstract]. Proc ASCO 2004, 23:4013.
38. Van Cutsem E, van de Velde H, Karasek P, et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004, 22:1430-1438.
39. Lersch C, Van Cutsem E, Amado R, et al.: Randomized phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas [abstract]. Proc ASCO 2001, 20:608.
40. Burch PA, Alberts SR, Schroeder MT, et al.: Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma (ACA): A North Central Cancer Treatment Group (NCCTG) phase II study [abstract]. Proc ASCO 2003, 22:1038.
41. Moore MJ, Hamm J, Dancey J, et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003 21:3296-3302.
42. Bramhall SR, Schulz J, Nemunaitis J, et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87:161-167.
43. Bramhall SR, Rosemurgy A, Brown PD, et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447-3455.
44. Brett BT, Smith SC, Bouvier CV, et al.: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002, 20:4225-4231.
45. Gilliam AD, Topuzov EG, Garin AM, et al.: Randomized, double blind, placebo-controlled, multi-center, group-sequential trial of G17DT for patients with advanced pancreatic cancer unsuitable or unwilling to take chemotherapy [abstract]. Proc ASCO 2004, 23:2511.
46. Seo Y, Baba H, Fukuda T, et al.: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88:2239-2245.
47. Itakura J, Ishiwata T, Shen B, et al.: Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000, 85:27-34.
48. Kindler HL, Friberg G, Stadler WM, et al.: Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial [abstract]. Proc ASCO 2004, 23:4009.
49. Maples WJ, Stevenson J, Sumrall SV, et al.: Advanced pancreatic cancer: a multi-institutional trial with gemcitabine and thalidomide [abstract]. Proc ASCO 2004, 23:4082.
50. Williams CS, Tsujii M, Reese J, et al.: Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000, 105:1589-1594.
51. Marini G, Simoncini E, Valcamonico F, et al.: Gemcitabine (Gem) plus celecoxib in advanced pancreatic carcinoma: a phase II study [abstract]. Proc ASCO 2004, 23:4103.
52. Xiong HQ, Rosenberg A, LoBuglio A, et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004, 22:2610-616.
53. Safran H, Ramanathan R, Schwartz J, et al.: Herceptin and gemcitabine for metastatic pancreatic cancers that over-express HER-2/neu [abstract]. Proc ASCO 2001, 20:517.
54. Porterfield B, Dragovich T, Patnaik A, et al.: Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: results from a phase IB trial [abstract]. Proc ASCO 2004, 23:4110.
55. OSI Pharmaceuticals I: Tarceva plus gemcitabine improves survival compared to gemcitabine alone in first-line pancreatic cancer patients. Press release. September 20, 2004.
56. Hwang RF, Yokoi K, Bucana CD, et al.: Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003, 9:6534-6544.
57. Ebert M, Nitsche B, Roecken C, et al.: A prospective and randomized clinical trial of the tyrosine kinase inhibitor imatinib mesylate as an initial therapy of advanced pancreatic cancer [abstract]. Proc ASCO 2004, 23:4151.
58. Abdollahi A, Lipson KE, Sckell A, et al.: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003, 63:8890-8898.
59. Siu L, Takimoto C, Awada A, et al.: A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer [abstract]. Proc ASCO 2004, 23:3059.